Imatinib
Monoclonal Gammopathy Of Uncertain Significance
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Monoclonal Gammopathy Of Uncertain Significance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dfn-15 National Cancer Institute (NCI) | Phase 2 | B |
Metformin Dana-Farber Cancer Institute | Phase 2 | CCC |
Isatuximab Assistance Publique - Hôpitaux de Paris | Phase 2 | CCC |
Linvoseltamab Regeneron Pharmaceuticals | Phase 2 | CCC |
Tetanus-Cmv Fusion Peptide Vaccine City of Hope Medical Center | Phase 1 | CC |
View all 13 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →